Copy
View this email in your browser
Purification of drugs is key to their safety and success
According to CSO at BIA Separations, Pete Gagnon, purification is key to the safety and consequently to biologics' commercial success. The tools developed by BIA are, according to Gagnon, particularly suited for purifying components for gene therapy, which is applied to correct flawed gene sequences in the DNA to cure genetic disease.
In this article you can find more information on challenges of purification process and how BIA Separations' smart media have become a part of registered drugs, which means its products will be used for the next several years.
Upon the visit of US Ambassador, BIA Separations announces production expansion to North America
On February 12, the US Ambassador to Slovenia Lynda C. Blancard visited BIA Separations. She was introduced to the innovative technologies developed in Slovenia and to company's plans that include launching a six million euros investment in the new facility in the Primorska region in March to create 100 new jobs. Due to the high demand for products and to fulfil the needs of US customers who represent the most important market for BIA Separations, they plan to expand production to the US or Canada. Here you can find our full official press release.
A method for concentration and purification of human coronavirus HCoV-OC43 using CIM QA monolithic columns
Human coronavirus is a frequent cause of respiratory tract illness, ranging from common cold to severe disease. The research on coronaviruses requires a quality material of high purity. Unfortunately, virus preparations are highly contaminated with cell debris and purification requires laborious, cost-ineffective procedures.
Here, we report a simple and efficient method for coronavirus concentration and purification, performed on CIM QA monolithic columns, with immobilized positively charged quaternary amines.
BIA Separations and University of Zagreb Sign License Agreement to Commercialize Novel Elution Method for Virus and Viral Vector Purification

BIA Separations announced it has signed a licensing agreement with the University of Zagreb to commercialize a novel elution method that helps preserve the integrity, infectivity and potency of viruses during immunoaffinity purification. University of Zagreb will provide BIA Separations with access to proprietary technology, while BIA Separations will market the technology to biopharma, biotech and life science industries globally. 
For further information click here.
Development and Characterization of PEGylated Chromatographic Monoliths as a Novel Platform for the Separation of PEGylated RNase a Isomers
PEGylated or polyethylene glycol-modified proteins have been used as therapeutic agents in different diseases. However, the major drawback in their procurement is the purification process to separate unreacted proteins and the PEGylated species. This article presents the use of CIM monoliths modified with PEG to separate PEGylated RNase A.
We invite you to meet us at:
The remarkable monolithic technology is opening up boundless new possibilites for accelerated gene therapy development. Do you want to learn more about it?
 
Join us at 9th Monolith Summer Symposium and get an in-depth experience that will take your gene therapy projects to another level.
Register now
Early bird discount (15% off) prolonged till March 31, 2020.
FEATURING TALKS FROM
Venkata Indurthi, Aldevron, USA
Robert Hodge, Avexis, USA
Andrew Knudten, Gene Therapy Consulting LLS, USA
Franz Gerner, Axovant, USA
James Michael Hatfield, Atticus BioConsulting LLC, USA
Thomas Linke, AstraZeneca, USA
Kazuhiro Oka, Baylor College of Medicine, USA
Nermin Ibreljic, Sarepta Therapeutics, USA

...and many more!
CALL FOR POSTERS
Excellence has no limits: tell us how you did it.
Do not be shy to share your knowledge and experience with monolith technology  :)
 
Poster abstract submission deadline: 31 March 2020
Facebook
Twitter
Website
LinkedIn
Copyright © 2020 BIA Separations, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp